May 14, 2025
Patholytix introduced a new era for digital pathology, but even for those familiar with our platform, there are capabilities and use cases that remain under the radar. This article highlights five powerful but lesser-known facts about Patholytix, each one opening new possibilities for how pathology teams can work smarter, scale faster, and deliver deeper insight across the research lifecycle.
1. Patholytix is already used by 9 of the top 10 global pharma companies
What began as a digital peer review tool for GLP studies has evolved into foundational infrastructure for some of the industry’s most complex R&D environments. Patholytix is now deployed across top 10 global pharma organisations, supporting a range of study types from early toxicology to advanced exploratory research. These customers rely on Patholytix not only to ensure compliant study execution, but to streamline their internal and outsourced workflows across CROs, collaborators, and global pathology teams. Whether deployed as part of a GLP programme or embedded in pre-IND research pipelines, Patholytix enables faster review, structured study management, and confident handoff to regulatory and downstream teams.
2. Our scanning team has digitised over 1 million slides for a single sponsor
Patholytix is more than software. Through our tech-enabled services arm, we support high-throughput scanning, metadata curation, and archival digitisation for some of the largest slide repositories in the industry. In one collaboration with a major pharma sponsor, the Patholytix scanning team digitised over one million glass slides, unlocking decades of preclinical data for reuse in AI model development, cross-study analysis, and regulatory submission. These scanning-first partnerships also serve as an onboarding pathway for teams not yet ready to commit to full digital pathology infrastructure. By starting with digitisation, they gain immediate access to structured image data, delivered via a hosted Patholytix instance with no internal IT lift required.
3. Our AI models are trained on the largest regulated preclinical pathology dataset in the market
Patholytix AI is built differently. Unlike tools trained on academic or clinical samples, our models are developed using the world’s largest dataset of regulated non-clinical pathology images. This includes study data spanning species, organs, dose groups, and lesion types. In partnership with a global pharmaceutical partner, we are developing AI tools for lesion detection, study triage, and virtual control groups, all designed to support regulatory-grade use cases in toxicologic pathology. These models are already being used to prioritise reviewer attention, standardise grading, and streamline concordance between readers, particularly in high-volume safety studies where the majority of slides show no significant findings.
4. Patholytix scales from lean biotech teams to global enterprise deployments
While Patholytix is trusted by global enterprise customers, the platform is equally suited to lean teams operating in focused or early-stage environments. Small biotechs, academic consortia, and translational researchers use Patholytix for digitising targeted studies, enabling virtual peer review, or archiving select data packages for future use. A single hosted instance can support cross-site collaboration, regulatory validation, and AI-driven review without requiring local infrastructure. Because Patholytix is modular and scalable, customers can adopt only what they need today, then expand into full GLP workflows or integrated scoring pipelines as their digital maturity grows. This flexibility is one of the reasons our footprint continues to grow across emerging biopharma.
5. It’s not just for drug safety
Although Patholytix is deeply embedded in GLP workflows, its capabilities extend well beyond traditional toxicology. Today, customers use the platform for translational studies, mechanism-of-action research, disease modelling, and biomarker development. Our study-centric structure and metadata tools make it ideal for longitudinal datasets, tissue atlases, or AI training pipelines that require high-quality image curation and reproducibility. With built-in support for retrospective analysis, structured re-annotation, and AI overlay visualisation, Patholytix is fast becoming the infrastructure layer for pathology-led insight across the full non-clinical research continuum, not just at the point of regulatory submission.
Conclusion
As Patholytix continues to evolve, so do the ways our customers use it. Whether digitising archives, accelerating peer review, training AI, or building digital-ready infrastructure, the platform is helping reshape how pathology contributes to discovery, safety, and translational science. These five facts are just the beginning and they reflect our broader mission: to unlock the full value of pathology data at every stage of research.
To explore how Patholytix can support your team, contact us or book a demo
Patholytix introduced a new era for digital pathology, but even for those familiar with our platform, there are capabilities and use cases that remain under the radar. This article highlights five powerful but lesser-known facts about Patholytix, each one opening new possibilities for how pathology teams can work smarter, scale faster, and deliver deeper insight across the research lifecycle.
1. Patholytix is already used by 9 of the top 10 global pharma companies
What began as a digital peer review tool for GLP studies has evolved into foundational infrastructure for some of the industry’s most complex R&D environments. Patholytix is now deployed across top 10 global pharma organisations, supporting a range of study types from early toxicology to advanced exploratory research. These customers rely on Patholytix not only to ensure compliant study execution, but to streamline their internal and outsourced workflows across CROs, collaborators, and global pathology teams. Whether deployed as part of a GLP programme or embedded in pre-IND research pipelines, Patholytix enables faster review, structured study management, and confident handoff to regulatory and downstream teams.
2. Our scanning team has digitised over 1 million slides for a single sponsor
Patholytix is more than software. Through our tech-enabled services arm, we support high-throughput scanning, metadata curation, and archival digitisation for some of the largest slide repositories in the industry. In one collaboration with a major pharma sponsor, the Patholytix scanning team digitised over one million glass slides, unlocking decades of preclinical data for reuse in AI model development, cross-study analysis, and regulatory submission. These scanning-first partnerships also serve as an onboarding pathway for teams not yet ready to commit to full digital pathology infrastructure. By starting with digitisation, they gain immediate access to structured image data, delivered via a hosted Patholytix instance with no internal IT lift required.
3. Our AI models are trained on the largest regulated preclinical pathology dataset in the market
Patholytix AI is built differently. Unlike tools trained on academic or clinical samples, our models are developed using the world’s largest dataset of regulated non-clinical pathology images. This includes study data spanning species, organs, dose groups, and lesion types. In partnership with a global pharmaceutical partner, we are developing AI tools for lesion detection, study triage, and virtual control groups, all designed to support regulatory-grade use cases in toxicologic pathology. These models are already being used to prioritise reviewer attention, standardise grading, and streamline concordance between readers, particularly in high-volume safety studies where the majority of slides show no significant findings.
4. Patholytix scales from lean biotech teams to global enterprise deployments
While Patholytix is trusted by global enterprise customers, the platform is equally suited to lean teams operating in focused or early-stage environments. Small biotechs, academic consortia, and translational researchers use Patholytix for digitising targeted studies, enabling virtual peer review, or archiving select data packages for future use. A single hosted instance can support cross-site collaboration, regulatory validation, and AI-driven review without requiring local infrastructure. Because Patholytix is modular and scalable, customers can adopt only what they need today, then expand into full GLP workflows or integrated scoring pipelines as their digital maturity grows. This flexibility is one of the reasons our footprint continues to grow across emerging biopharma.
5. It’s not just for drug safety
Although Patholytix is deeply embedded in GLP workflows, its capabilities extend well beyond traditional toxicology. Today, customers use the platform for translational studies, mechanism-of-action research, disease modelling, and biomarker development. Our study-centric structure and metadata tools make it ideal for longitudinal datasets, tissue atlases, or AI training pipelines that require high-quality image curation and reproducibility. With built-in support for retrospective analysis, structured re-annotation, and AI overlay visualisation, Patholytix is fast becoming the infrastructure layer for pathology-led insight across the full non-clinical research continuum, not just at the point of regulatory submission.
Conclusion
As Patholytix continues to evolve, so do the ways our customers use it. Whether digitising archives, accelerating peer review, training AI, or building digital-ready infrastructure, the platform is helping reshape how pathology contributes to discovery, safety, and translational science. These five facts are just the beginning and they reflect our broader mission: to unlock the full value of pathology data at every stage of research.
To explore how Patholytix can support your team, contact us or book a demo
フォロー
Ireland
DCU Alpha Building, Innovation Campus,
11 Old Finglas Rd, Glasnevin, Co. Dublin D11 KXN4
